Dorzolamide/timolol combination has hypotensive and haemodynamic effects

Article

A fixed combination of dorzolamide and timolol significantly increase blood flow at the neuroretinal rim, demonstrating a combination of hypotensive and haemodynamic effects.

A fixed combination of dorzolamide and timolol significantly increase blood flow at the neuroretinal rim, demonstrating a combination of hypotensive and haemodynamic effects, according to a report published online ahead of print by Eye.

Teresa Rolle and colleagues from the University of Torino, Italy compared the effect of dorzolamide hydrochloride 2%, timolol maleate 0.5% and their fixed combination on intraocular pressure (IOP) and retinal and optic nerve head haemodynamics in 28 patients with primary open angle glaucoma.

After a four-week wash-out period, patients were randomized into two groups: group 1 received dorzolamide 2% monotherapy and group 2 received timolol 0.5% monotherapy. Following this period, both groups switched to a fixed combination of the two drugs for four-weeks. IOP, ocular diastolic perfusion pressure (ODPP), heart rate and scanning laser Doppler flowmetry measurements at the peripapillary retina and neuroretinal rim were taken at enrolment (T0), wash-out (T1), during monotherapy (T3) and during combination therapy (T4).

At T1 and T3, IOP had decreased significantly in group 1 (p<0.001) and in group 2 (p<0.001). At the same intervals, blood flow increased significantly at rim level in group 1 (p<0.05). Between intervals of T1 and T3, a significant increase in ODPP was observed in both groups.

The authors of this study believe that a fixed combination of dorzolamide and timolol significantly increases blood flow at the neuroretinal rim.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.